600420 国药现代
已收盘 09-10 15:00:00
资讯
新帖
简况
国药现代(600420.SH)子公司盐酸戊乙奎醚注射液获得药品注册证书
智通财经 · 16:23
国药现代(600420.SH)子公司盐酸戊乙奎醚注射液获得药品注册证书
国药现代：将国药现代打造成为创新驱动型，中国领先、国际一流的制药企业
证券之星 · 09-04
国药现代：将国药现代打造成为创新驱动型，中国领先、国际一流的制药企业
国药现代：2025年末，公司研发人员数量为1429人
证券之星 · 09-04
国药现代：2025年末，公司研发人员数量为1429人
国药现代新注册《国药现代数据中台V1.0》项目的软件著作权
证券之星 · 09-04
国药现代新注册《国药现代数据中台V1.0》项目的软件著作权
国药现代（600420）披露2026年半年度业绩说明会安排，9月2日股价下跌0.81%
证券之星 · 09-02
国药现代（600420）披露2026年半年度业绩说明会安排，9月2日股价下跌0.81%
国药现代最新公告：获得布瑞哌唑片药品注册证书
证券之星 · 08-28
国药现代最新公告：获得布瑞哌唑片药品注册证书
国药现代：公司在产品研发方面如有重大进展，将及时履行信息披露义务
证券之星 · 08-28
国药现代：公司在产品研发方面如有重大进展，将及时履行信息披露义务
国药现代：根据监管规则本次交易不涉及对赌
证券之星 · 08-28
国药现代：根据监管规则本次交易不涉及对赌
国药现代：国瑞药业无水乙醇注射液（20ml）为2.4类改良型新药
证券之星 · 08-28
国药现代：国瑞药业无水乙醇注射液（20ml）为2.4类改良型新药
国药现代：收购国瑞药业能够与公司发挥业务协同作用
证券之星 · 08-28
国药现代：收购国瑞药业能够与公司发挥业务协同作用
国药现代：2026年公司中期现金分红占当期归属于上市公司股东的净利润的24.33%
证券之星 · 08-28
国药现代：2026年公司中期现金分红占当期归属于上市公司股东的净利润的24.33%
图解国药现代中报：第二季度单季净利润同比下降55.84%
证券之星 · 08-27
图解国药现代中报：第二季度单季净利润同比下降55.84%
国药现代：公司将定期汇总包括上证互动易在内的各个渠道的投资者建议，并报告给董事会及公司相关领导
证券之星 · 08-20
国药现代：公司将定期汇总包括上证互动易在内的各个渠道的投资者建议，并报告给董事会及公司相关领导
国药现代：聚焦核心优势领域，综合研判积极推进科研工作
证券之星 · 08-20
国药现代：聚焦核心优势领域，综合研判积极推进科研工作
股市必读：国药现代新发布《关于全资子公司药品通过仿制药一致性评价的公告》
证券之星 · 08-20
股市必读：国药现代新发布《关于全资子公司药品通过仿制药一致性评价的公告》
国药现代最新公告：拟4.06亿元收购国瑞药业51%股权
证券之星 · 08-19
国药现代最新公告：拟4.06亿元收购国瑞药业51%股权
国药现代（600420）披露全资子公司药品通过仿制药一致性评价公告，8月18日股价下跌0.57%
证券之星 · 08-18
国药现代（600420）披露全资子公司药品通过仿制药一致性评价公告，8月18日股价下跌0.57%
国药现代最新公告：子公司维生素B12注射液通过一致性评价
证券之星 · 08-18
国药现代最新公告：子公司维生素B12注射液通过一致性评价
股市必读：国药现代新发布《关于全资子公司药品通过仿制药一致性评价的公告》
证券之星 · 08-17
股市必读：国药现代新发布《关于全资子公司药品通过仿制药一致性评价的公告》
国药现代（600420）披露全资子公司药品通过仿制药一致性评价公告，8月14日股价上涨0.11%
证券之星 · 08-14
国药现代（600420）披露全资子公司药品通过仿制药一致性评价公告，8月14日股价上涨0.11%
加载更多
公司概况
公司名称：
上海现代制药股份有限公司
所属行业：
医药制造业
上市日期：
2004-06-16
主营业务：
上海现代制药股份有限公司的主营业务是医药产品研发、生产与销售。公司的主要产品是医药中间体、原料药、化学制剂、动物疫苗、大健康。
发行价格：
8.08
{"stockData":{"symbol":"600420","market":"SH","secType":"STK","nameCN":"国药现代","latestPrice":8.46,"timestamp":1789023600000,"preClose":8.49,"halted":0,"volume":8049602,"delay":0,"changeRate":-0.0035,"floatShares":1341000000,"shares":1341000000,"eps":0.4065,"marketStatus":"已收盘","change":-0.03,"latestTime":"09-10 15:00:00","open":8.49,"high":8.52,"low":8.36,"amount":67783400,"amplitude":0.0188,"askPrice":8.46,"askSize":141,"bidPrice":8.45,"bidSize":380,"shortable":0,"etf":0,"ttmEps":0.4065,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789090200000},"marketStatusCode":5,"adr":0,"adjPreClose":8.49,"symbolType":"stock","openAndCloseTimeList":[[1789003800000,1789011000000],[1789016400000,1789023600000]],"highLimit":9.34,"lowLimit":7.64,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1341172692,"isCdr":false,"pbRate":0.82,"roa":"--","peRate":20.811808,"roe":"1.99%","epsLYR":0.7021,"committee":-0.465869,"marketValue":11346000000,"turnoverRate":0.006,"status":1,"floatMarketCap":11346000000},"requestUrl":"/m/hq/s/600420","defaultTab":"news","newsList":[{"id":"2666573566","title":"国药现代(600420.SH)子公司盐酸戊乙奎醚注射液获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2666573566","media":"智通财经","labels":["productRelease"],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666573566?lang=zh_cn&edition=full","pubTime":"2026-09-10 16:23","pubTimestamp":1789028589,"startTime":"0","endTime":"0","summary":"智通财经APP讯，国药现代 发布公告，近日，公司全资子公司国药集团工业有限公司收到国家药品监督管理局核准签发的盐酸戊乙奎醚注射液《药品注册证书》。据悉，国药工业已于2025年9月获得盐酸戊乙奎醚注射液药品注册证书并通过一致性评价，此次新增规格并通过一致性评价，将进一步丰富公司产品群，有利于进一步增强公司在相关用药领域的综合市场竞争力，为公司未来发展带来积极影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494392.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"国药现代(600420.SH)子公司盐酸戊乙奎醚注射液获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0020","BK0132","600420","BK0082","BK0239","BK0010"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664338244","title":"国药现代：将国药现代打造成为创新驱动型，中国领先、国际一流的制药企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2664338244","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664338244?lang=zh_cn&edition=full","pubTime":"2026-09-04 17:15","pubTimestamp":1788513320,"startTime":"0","endTime":"0","summary":"证券之星消息，国药现代(600420)09月04日在投资者关系平台上答复投资者关心的问题。投资者提问：SpaceX星际文明 招股书的第一句话听起来就感觉很厉害。sx讲我们的使命是：构建使生命成为多行星物种所必需的系统与技术，理解宇宙的真实本质，并将意识之光延伸至群星。先不讲公司和业绩好坏，单这个公司使命定位都很赞！尊敬的领导，您好，请问贵公司的使命是什么？国药现代回复：尊敬的投资者：您好！公司的长期愿景是将国药现代打造成为创新驱动型，中国领先、国际一流的制药企业，做有活力、有实力、有影响力的行业引领者。感谢您的关注！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400030051.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","BK0082","BK0132","BK1191","BK0239","600420","BK1574","BK0020","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664338972","title":"国药现代：2025年末，公司研发人员数量为1429人","url":"https://stock-news.laohu8.com/highlight/detail?id=2664338972","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664338972?lang=zh_cn&edition=full","pubTime":"2026-09-04 17:12","pubTimestamp":1788513138,"startTime":"0","endTime":"0","summary":"证券之星消息，国药现代09月04日在投资者关系平台上答复投资者关心的问题。听起来很厉害，但是关于公司的研发有几点疑惑:1、市场对贵司的研发人员一无所知，请具体介绍一下贵司较重磅带分量的研发人员情况。2025年末，公司研发人员数量为1429人，占公司总人数的14.74%。在产品研发方面如有重大进展，公司将及时履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400029968.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","600420","BK0132","BK0239","BK0010","BK0020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664806625","title":"国药现代新注册《国药现代数据中台V1.0》项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2664806625","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664806625?lang=zh_cn&edition=full","pubTime":"2026-09-04 02:07","pubTimestamp":1788458833,"startTime":"0","endTime":"0","summary":"证券之星消息，近日国药现代（600420）新注册了《国药现代数据中台V1.0》项目的软件著作权。今年以来国药现代新注册软件著作权1个。结合公司2026年中报财务数据，今年上半年公司在研发方面投入了1.68亿元，同比减26.61%。通过天眼查大数据分析，上海现代制药股份有限公司共对外投资了22家企业，参与招投标项目7964次；财产线索方面有商标信息139条，专利信息142条，著作权信息1条；此外企业还拥有行政许可279个。数据来源：天眼查APP以上内容为证券之星据公开信息整理，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400002460.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0020","159180","BK0082","BK0010","BK0132","BK0239","600420"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664810739","title":"国药现代（600420）披露2026年半年度业绩说明会安排，9月2日股价下跌0.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664810739","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664810739?lang=zh_cn&edition=full","pubTime":"2026-09-02 23:05","pubTimestamp":1788361520,"startTime":"0","endTime":"0","summary":"截至2026年9月2日收盘，国药现代报收于8.52元，较前一交易日下跌0.81%，最新总市值为114.27亿元。该股当日开盘8.59元，最高8.62元，最低8.49元，成交额达6177.21万元，换手率为0.54%。近日，国药现代披露关于召开2026年半年度业绩说明会的公告。公司将于2026年9月8日15:00-16:00通过网络互动方式召开2026年半年度业绩说明会，会议地点为价值在线。公司将就2026年半年度经营成果、财务状况等投资者关注的问题进行交流。会议结束后可通过价值在线查看召开情况及主要内容。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200043493.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","BK0132","600420","BK0239","BK0020","BK0010"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662683110","title":"国药现代最新公告：获得布瑞哌唑片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2662683110","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662683110?lang=zh_cn&edition=full","pubTime":"2026-08-28 16:42","pubTimestamp":1787906565,"startTime":"0","endTime":"0","summary":"国药现代(600420.SH)公告称，公司收到国家药品监督管理局核准签发的布瑞哌唑片《药品注册证书》。该药品为化学药品4类，主要用于治疗成人精神分裂症。截至公告日，公司在该项目累计研发投入约1231.55万元。本次获得注册证书有利于增强公司在精神治疗领域的竞争力，但对当期经营业绩无重大影响。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800038518.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","600420","BK0132","BK0239","BK0010","BK0020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662132052","title":"国药现代：公司在产品研发方面如有重大进展，将及时履行信息披露义务","url":"https://stock-news.laohu8.com/highlight/detail?id=2662132052","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662132052?lang=zh_cn&edition=full","pubTime":"2026-08-28 15:33","pubTimestamp":1787902425,"startTime":"0","endTime":"0","summary":"研发方面，AI辅助药物开发已覆盖小分子、ADC、siRNA、OAPD、分子胶、TME六大技术平台，横跨肿瘤、心血管/代谢、呼吸/自免、外科/镇痛等多个治疗领域。贵司大量资金躺在账上和国药财务，能拿出一部分往创新研发和AI制药上发发力吗？公司在产品研发方面如有重大进展，将及时履行信息披露义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800031369.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0020","BK0010","BK0239","BK0132","BK0082","600420"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662605214","title":"国药现代：根据监管规则本次交易不涉及对赌","url":"https://stock-news.laohu8.com/highlight/detail?id=2662605214","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662605214?lang=zh_cn&edition=full","pubTime":"2026-08-28 15:33","pubTimestamp":1787902423,"startTime":"0","endTime":"0","summary":"证券之星消息，国药现代(600420)08月28日在投资者关系平台上答复投资者关心的问题。投资者提问：贵司拟4.06亿元收购国瑞药业51%股权，请问怎么没有三年业绩对赌协议呢？ 另外国瑞药业持有麻醉药生产资格牌照吗？国药现代回复：尊敬的投资者：您好！根据监管规则本次交易不涉及对赌；目前，国瑞药业具备一类精神药品生产资质，但无麻醉药生产资质。感谢您的关注！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800031365.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600420","BK0082","BK0132","BK0239","BK0020","BK0010"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662524650","title":"国药现代：国瑞药业无水乙醇注射液（20ml）为2.4类改良型新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2662524650","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662524650?lang=zh_cn&edition=full","pubTime":"2026-08-28 15:33","pubTimestamp":1787902422,"startTime":"0","endTime":"0","summary":"贵司收购国瑞药业后，请问全公司加上国瑞旗下镇痛麻精药，阿片类镇痛等麻醉药品一共有多少品种品样，请全部名字列举一下，谢谢。国瑞药业无水乙醇注射液为2.4类改良型新药，主要适应症为单纯性肾囊肿。CDE网站显示，成都倍特药业股份有限公司的无水乙醇注射液已于2026年6月获得药品注册证书。目前，国瑞药业具备一类精神药品生产资质，但无麻醉药生产资质。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800031364.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","BK0010","BK0132","BK0239","600420","BK0020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662052488","title":"国药现代：收购国瑞药业能够与公司发挥业务协同作用","url":"https://stock-news.laohu8.com/highlight/detail?id=2662052488","media":"证券之星","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662052488?lang=zh_cn&edition=full","pubTime":"2026-08-28 15:33","pubTimestamp":1787902391,"startTime":"0","endTime":"0","summary":"上市公司近年业绩已呈持续下滑态势，在此背景下，公司是否具备经营好一家亏损持续扩大企业的能力，令人存疑。收购国瑞药业能够与公司发挥业务协同作用，公司也将从管理融合、产品互补、研发统筹、市场渠道共享等方面促进优势互补与资源嫁接，积极提振国瑞药业经营效益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800031333.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600420","BK0010","BK0020","BK0132","BK0082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662052103","title":"国药现代：2026年公司中期现金分红占当期归属于上市公司股东的净利润的24.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662052103","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662052103?lang=zh_cn&edition=full","pubTime":"2026-08-28 15:33","pubTimestamp":1787902391,"startTime":"0","endTime":"0","summary":"恳请公司予以说明。公司坚持稳定、一贯的现金分红政策。2025年公司中期现金分红占当期归属于上市公司股东净利润比例为19.96%，2026年公司中期现金分红占当期归属于上市公司股东的净利润的24.33%。公司将遵循《未来三年股东回报规划》，2025年-2027年，公司在经营状况良好、现金流能够满足正常经营和长期发展需求的前提下，若无重大投资计划或重大现金支出等事项发生，公司每年以现金方式分配的利润不少于当年实现的归属于上市公司股东净利润的40%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800031331.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600420"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662173746","title":"图解国药现代中报：第二季度单季净利润同比下降55.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662173746","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662173746?lang=zh_cn&edition=full","pubTime":"2026-08-27 01:34","pubTimestamp":1787765698,"startTime":"0","endTime":"0","summary":"证券之星消息，国药现代2026年中报显示，上半年度公司主营收入39.4亿元，同比下降19.22%；归母净利润2.76亿元，同比下降58.99%；扣非净利润2.56亿元，同比下降59.85%；其中2026年第二季度，公司单季度主营收入18.76亿元，同比下降17.4%；单季度归母净利润1.37亿元，同比下降55.84%；单季度扣非净利润1.1亿元，同比下降62.22%；负债率17.76%，投资收益4879.89万元，财务费用1591.36万元，毛利率29.6%。财报数据概要请见下图:本文数据来源于国药现代2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700004713.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600420"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660400684","title":"国药现代：公司将定期汇总包括上证互动易在内的各个渠道的投资者建议，并报告给董事会及公司相关领导","url":"https://stock-news.laohu8.com/highlight/detail?id=2660400684","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660400684?lang=zh_cn&edition=full","pubTime":"2026-08-20 17:21","pubTimestamp":1787217678,"startTime":"0","endTime":"0","summary":"证券之星消息，国药现代08月20日在投资者关系平台上答复投资者关心的问题。公司将定期汇总包括上证互动易在内的各个渠道的投资者建议，并报告给董事会及公司相关领导。如您有具体的建议，欢迎提出，我们将转送有关责任部门研究。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000030540.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0020","BK0082","BK0239","600420","BK0010","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660400686","title":"国药现代：聚焦核心优势领域，综合研判积极推进科研工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2660400686","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660400686?lang=zh_cn&edition=full","pubTime":"2026-08-20 17:21","pubTimestamp":1787217674,"startTime":"0","endTime":"0","summary":"证券之星消息，国药现代08月20日在投资者关系平台上答复投资者关心的问题。投资者提问：80%以上的央企都在立项自己行业科研创新攻坚项目，目的要突破国外技术封锁，完全自主可控！公司将本着为股东负责的原则，围绕战略规划，聚焦核心优势领域，综合研判积极推进科研工作，持续优化产品管线布局，推动公司高质量研发。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000030536.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","BK0239","BK0082","BK0132","600420","BK0020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660342703","title":"股市必读：国药现代新发布《关于全资子公司药品通过仿制药一致性评价的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2660342703","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660342703?lang=zh_cn&edition=full","pubTime":"2026-08-20 02:06","pubTimestamp":1787162776,"startTime":"0","endTime":"0","summary":"公司公告汇总：董事会选举冯军为董事长，并审议通过以40,636.34万元收购国药集团国瑞药业51%股权的关联交易议案。公司公告汇总：全资子公司维生素B12注射液新增1ml:1mg规格并获批通过仿制药一致性评价。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000002042.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","600420","BK0239","BK0082","BK0010","BK0020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660440224","title":"国药现代最新公告：拟4.06亿元收购国瑞药业51%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2660440224","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660440224?lang=zh_cn&edition=full","pubTime":"2026-08-19 18:25","pubTimestamp":1787135134,"startTime":"0","endTime":"0","summary":"国药现代(600420.SH)公告称，公司以现金4.06亿元收购国药集团国瑞药业51%股权，交易对方为国药集团、国药控股及国药股份。收购完成后，国瑞药业将成为公司控股子公司，此举旨在消除同业竞争，丰富神经系统、抗感染等领域产品管线。本次交易构成关联交易，不构成重大资产重组，无需提交股东会审议。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900032485.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600420","BK0010","BK0239","BK0020","BK0132","BK0082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660911493","title":"国药现代（600420）披露全资子公司药品通过仿制药一致性评价公告，8月18日股价下跌0.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660911493","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660911493?lang=zh_cn&edition=full","pubTime":"2026-08-18 22:30","pubTimestamp":1787063434,"startTime":"0","endTime":"0","summary":"截至2026年8月18日收盘，国药现代报收于8.65元，较前一交易日下跌0.57%，最新总市值为116.01亿元。近日，上海现代制药股份有限公司全资子公司国药集团容生制药有限公司收到国家药品监督管理局核准签发的《药品补充申请批准通知书》，批准维生素B12注射液增加1ml:1mg规格，并通过仿制药质量和疗效一致性评价。截至目前，国药容生该项目累计研发投入约316.32万元。本次通过一致性评价有利于产品未来市场拓展和销售，但对当期经营业绩无重大影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800042664.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","600420","BK0132","BK0239","BK0010","BK0020"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660546631","title":"国药现代最新公告：子公司维生素B12注射液通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2660546631","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660546631?lang=zh_cn&edition=full","pubTime":"2026-08-18 17:40","pubTimestamp":1787046012,"startTime":"0","endTime":"0","summary":"国药现代(600420.SH)公告称，公司全资子公司国药容生收到国家药监局核准签发的《药品补充申请批准通知书》，批准维生素B12注射液增加1ml:1mg规格并通过仿制药质量和疗效一致性评价。该药品主要用于巨幼细胞性贫血及神经系统病变辅助治疗。2025年该药品在全国公立医疗机构及城市药店销售额为6718万元。截至目前，国药容生累计研发投入约316.32万元。此次过评有利于产品市场拓展，但对公司当期经营业绩不会产生重大影响。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800031248.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","BK0132","600420","BK0239","BK0020","BK0010"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660170845","title":"股市必读：国药现代新发布《关于全资子公司药品通过仿制药一致性评价的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2660170845","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660170845?lang=zh_cn&edition=full","pubTime":"2026-08-17 01:20","pubTimestamp":1786900818,"startTime":"0","endTime":"0","summary":"公司公告汇总：全资子公司阿莫西林克拉维酸钾干混悬剂通过仿制药一致性评价，2025年该药品全国公立医疗机构及城市药店销售额为2.79亿元。公司公告汇总关于全资子公司药品通过仿制药一致性评价的公告上海现代制药股份有限公司全资子公司国药集团威奇达药业有限公司收到国家药品监督管理局核准签发的《药品补充申请批准通知书》，阿莫西林克拉维酸钾干混悬剂通过仿制药质量和疗效一致性评价。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700000489.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600420","BK0082","BK0132","BK0239","BK0020","BK0010"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659147982","title":"国药现代（600420）披露全资子公司药品通过仿制药一致性评价公告，8月14日股价上涨0.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659147982","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659147982?lang=zh_cn&edition=full","pubTime":"2026-08-14 22:14","pubTimestamp":1786716861,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘，国药现代报收于8.73元，较前一交易日上涨0.11%，最新总市值为117.08亿元。近日，上海现代制药股份有限公司全资子公司国药集团威奇达药业有限公司收到国家药品监督管理局核准签发的《药品补充申请批准通知书》，阿莫西林克拉维酸钾干混悬剂通过仿制药质量和疗效一致性评价。该药品主要用于治疗产酶细菌引起的感染，目前已有其他企业通过一致性评价。2025年该药品在全国公立医疗机构及城市药店销售额为2.79亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400040029.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","600420","BK0082","BK0020","BK0239","BK0010"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1789046981495,"stockEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":-0.0297},{"period":"3month","weight":-0.0059},{"period":"6month","weight":-0.2082},{"period":"1year","weight":-0.2264},{"period":"ytd","weight":-0.1409}],"compareEarnings":[{"period":"1week","weight":0.0026},{"period":"1month","weight":-0.0038},{"period":"3month","weight":-0.0089},{"period":"6month","weight":-0.0351},{"period":"1year","weight":0.0379},{"period":"ytd","weight":-0.0044}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海现代制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"35846人(较上一季度减少1.05%)","perCapita":"37414股","listingDate":"2004-06-16","address":"上海市浦东新区建陆路378号","registeredCapital":"134117万元","survey":" 上海现代制药股份有限公司的主营业务是医药产品研发、生产与销售。公司的主要产品是医药中间体、原料药、化学制剂、动物疫苗、大健康。","listedPrice":8.08},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"国药现代(600420)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供国药现代(600420)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"国药现代,600420,国药现代股票,国药现代股票老虎,国药现代股票老虎国际,国药现代行情,国药现代股票行情,国药现代股价,国药现代股市,国药现代股票价格,国药现代股票交易,国药现代股票购买,国药现代股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"国药现代(600420)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供国药现代(600420)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}